Insider Selling: CryoLife, Inc. (CRY) Director Sells $45,600.00 in Stock
CryoLife, Inc. (NYSE:CRY) Director James Benson sold 2,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $22.80, for a total transaction of $45,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of CryoLife, Inc. (CRY) opened at 23.65 on Friday. The company has a 50-day moving average price of $21.58 and a 200-day moving average price of $19.04. CryoLife, Inc. has a 12 month low of $14.03 and a 12 month high of $24.00. The company has a market capitalization of $791.00 million, a P/E ratio of 71.67 and a beta of 0.92.
CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. The company had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 earnings per share. On average, analysts forecast that CryoLife, Inc. will post $0.43 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/insider-selling-cryolife-inc-cry-director-sells-45600-00-in-stock/1615109.html.
Several equities research analysts have recently commented on the stock. BidaskClub lowered shares of CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research lowered shares of CryoLife from a “buy” rating to a “sell” rating in a report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.33.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its stake in CryoLife by 6.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock worth $39,107,000 after buying an additional 110,973 shares during the last quarter. Vanguard Group Inc. boosted its stake in CryoLife by 6.6% during the second quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock worth $33,090,000 after buying an additional 102,540 shares during the last quarter. Macquarie Group Ltd. boosted its stake in CryoLife by 18.6% during the second quarter. Macquarie Group Ltd. now owns 1,387,710 shares of the medical equipment provider’s stock worth $27,685,000 after buying an additional 217,283 shares during the last quarter. Northern Trust Corp boosted its stake in CryoLife by 7.4% during the second quarter. Northern Trust Corp now owns 1,171,769 shares of the medical equipment provider’s stock worth $23,377,000 after buying an additional 81,090 shares during the last quarter. Finally, State Street Corp boosted its stake in CryoLife by 5.2% during the second quarter. State Street Corp now owns 758,840 shares of the medical equipment provider’s stock worth $15,143,000 after buying an additional 37,279 shares during the last quarter. 68.44% of the stock is currently owned by institutional investors.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.